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Background and PurposezzTo evaluate changes in cortical excitability induced by zonisamide 
(ZNS) in focal epilepsy patients.
MethodszzTwenty-four drug-naїve focal epilepsy patients (15 males; overall mean age 29.8 years) 
were enrolled. The transcranial magnetic stimulation parameters obtained using two Magstim 200 
stimulators were the resting motor threshold, amplitude of the motor-evoked potential (MEP), 
cortical silent period, short intracortical inhibition, and intracortical facilitation. These five tran-
scranial magnetic stimulation parameters were measured before and after ZNS, and the findings 
were compared.
ResultszzAll 24 patients were treated with ZNS monotherapy (200-300 mg/day) for 8-12 weeks. 
After ZNS, MEP amplitudes decreased (-36.9%) significantly in epileptic hemispheres (paired 
t-test with Bonferroni’s correction for multiple comparisons, p<0.05), whereas the mean resting 
motor threshold, cortical silent period, short intracortical inhibition, and intracortical facilitation 
were unchanged (p>0.05). ZNS did not affect cortical excitability in nonepileptic hemispheres.
ConclusionszzThese findings suggest that ZNS decreases cortical excitability only in the epilep-
tic hemispheres of focal epilepsy patients. MEP amplitudes may be useful for evaluating ZNS-
induced changes in cortical excitability.  J Clin Neurol 2010;6:189-195
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Introduction
Focal epilepsy is defined by its epileptogenic zone, which is lim-
ited to one or more regions of the brain. Various diagnostic tools, 
including neuroimaging studies, have been used to localize the 
epileptic focus and understand the pathophysiology of focal 
epilepsy.
1-4 Transcranial magnetic stimulation (TMS) provides 
a well-established noninvasive means of investigating human 
motor cortex excitability.
5,6 TMS may serve as a marker of ex-
citatory/inhibitory imbalance in the cortical neurons of epilep-
sy patients because it detects relatively subtle alterations in the 
physiological state of the brain.
7 Published TMS results obtained 
in epilepsy patients are often conflicting. TMS studies have of-
ten been conducted in chronic epilepsy patients taking at least 
one antiepileptic drug (AED), and AEDs have been shown to 
affect several TMS parameters. It is therefore often difficult to 
separate intrinsic cortical excitability changes resulting from 
the epileptic condition and those associated with drug effects in 
patients. Furthermore, most TMS studies have been performed 
on healthy subjects, and the few studies performed in drug-
naïve epilepsy patients have produced disparate results.
8-10 
Nevertheless, a recent study on a large number of drug-naïve 
patients with new-onset epilepsy revealed hyperexcitability 
in brains affected by idiopathic generalized epilepsy (IGE) or 
focal epilepsy.
11
Zonisamide (ZNS) is an AED with proven efficacy as an ad-
junctive therapeutic agent in patients with partial seizures.
12-15 
ZNS is generally well tolerated and has a favorable pharmaco-
kinetic profile that permits once- or twice-daily administrations. 
ZNS appears to block the spread of seizure discharges and to 
suppress the epileptic focus, although the precise mechanism of 
its antiepileptic activity is unknown.
16 Based on the findings of 
cellular and animal studies, the suggested antiepileptic mech-
anisms of ZNS are as follows:16,17
1) Membrane stabilization (blockade of voltage-gated sodi-
um channels, inhibition of T-type voltage-gated calcium chan-Effect of Zonisamide on Cortical Excitability
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nels, and free-radical scavenging).
2) Neuromodulation (facilitation of dopaminergic and sero-
tonergic transmission, and blockade of potassium-evoked glu-
tamate-mediated excitatory synaptic transmission).
3) Neuroprotection (free-radical scavenging). 
A TMS study of the effects of ZNS on cortical excitability was 
performed in patients with generalized epilepsy.
18 After ZNS treat-
ment, the amplitudes of motor-evoked potentials (MEPs) were 
significantly reduced in both hemispheres (right, -34.2%; left, 
-37.0%), whereas other TMS parameters were not significant-
ly changed.
The aim of the present study was to determine the effect of ZNS 
monotherapy on cortical excitability in drug-naïve patients di-
agnosed with focal epilepsy.
Methods
Patients
We enrolled consecutive focal epilepsy patients who had not pre-
viously taken an AED. The diagnostic criteria of the International 
League Against Epilepsy (1989) were followed throughout. 
The following patient inclusion criteria were applied:
1) Clinically documented complex focal seizures or second-
arily generalized tonic-clonic seizures (SGTCS) with a lateraliz-
ing sign such as unilateral somatosensory/visual aura, dystonic 
posturing, or version.
2) Experience of more than two spontaneous epileptic sei-
zures.
3) Only one type of clinical seizure on history or on video-
electroencephalogram (EEG) monitoring.
4) Satisfactory localization of the epileptogenic area by in-
terictal or ictal epileptiform discharges on video-EEG moni-
toring during a typical seizure (including epileptic aura).
5) No multifocal or independent right- or left-hemisphere in-
terictal epileptiform discharges on EEG.
6) No history of antiepileptic medication.
7) No lesion in the motor cortex on brain magnetic reso-
nance imaging (MRI). If there no MRI abnormality concor-
dant with the location of interictal spikes was found, a long-
term video-EEG monitoring or 
18F-fluorodeoxyglucose–
positron-emission tomography was performed.
Patients with a history of head trauma, another neurological 
disease, or psychiatric disorders were excluded. Applying these 
criteria resulted in the inclusion of 24 patients in the study (aged 
29.8±6.5 years, mean±SD; epileptic focus: left in 13, right in 
11; temporal in 18, frontal in 2, parietal in 2, and occipital in 1). 
These and other patient characteristics are given in Table 1.
Twenty-seven patients underwent a TMS study before ZNS. 
During the 12-week period of ZNS therapy, two patients drop-
ped out (they arbitrarily discontinue medication) and one pa-
tient changed to another AED due to ZNS side effects. The re-
maining 24 patients became seizure free after 6 weeks of ZNS 
administration. Finally, 24 patients (15 males, 9 females) who 
were treated with ZNS for 8-9 weeks underwent TMS study 
after ZNS.
Study design
All 24 patients received ZNS as a monotherapy for 8-12 weeks. 
Steady-state concentrations of ZNS were achieved within 
14 days.
19 Before ZNS administration, all patients underwent 
a physical examination, routine blood test (hematology and 
chemistry panel including liver function tests), and brain MRI. 
The predetermined target dosage for ZNS was 200 mg/day, al-
though this depended on the individual. Our intention was to ad-
minister ZNS at 100 mg/day for the first 2 weeks, and then 200   
mg/day for the next 6 weeks. However, if seizures occurred in 
patients during the latter 6-week period, ZNS dosages were fur-
ther increased by 25 mg/day for a week in order to achieve a sei-
zure-free state for at least 2 weeks prior to the post-ZNS TMS 
study.
Moreover, when an intolerable adverse event was encountered 
due to ZNS administration, the dosage was decreased by 25 mg/
day for 1 week until the symptoms subsided. During the study 
period, a physician examined patients fortnightly; blood testing 
for hematology and liver function was performed twice before 
medication and again at the end of the study period. Physicians 
documented seizure frequency in detail in a seizure diary when 
patients visited the outpatient clinic.
TMS
MEPs were recorded using surface electromyography (EMG) 
electrodes placed over the first dorsal interosseus (FDI) muscle 
in a belly-tendon montage. Raw EMG signals were amplified 
and then bandpass filtered between 20 and 10 kHz. An audito-
ry feedback EMG signal was produced to ensure complete vol-
untary relaxation of the target muscle. TMS was delivered thr-
ough a focal figure-of-eight-shaped magnetic coil (70 mm 
internal diameter) connected to two Magstim 200 magnetic 
stimulators via a BiStim-module (Magstim, Camarthenshire, 
UK). Patients were seated in an armchair with their head 
fixed in a plastic foam headrest. The magnetic coil was 
placed over the motor cortex by finding and marking a scalp 
site that was producing maximal MEPs in the FDI muscle 
when the current induced in the brain flowed posterior to an-
terior approximately perpendicularly to the assumed line of 
the central sulcus.
18
TMS parameters of motor cortex excitability
1) The resting motor threshold (RMT) was defined as the low-
est stimulator output intensity capable of inducing MEPs with Joo EY et al.
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peak-to-peak amplitude of at least 50 µV in a relaxed FDI mus-
cle in at least four out of eight consecutive trials. A step width 
of 1% of maximum stimulator output was used to determine mo-
tor thresholds.
2) Peak-to-peak MEP amplitudes were measured in a relaxed 
FDI at three stimulus intensities (i.e., 120%, 140%, and 150% 
of the RMT). TMS stimuli (eight stimuli at each stimulus intensi-
ty) were delivered randomly 5 s apart, and average MEP ampli-
tudes were calculated at each intensity.
3) Cortical silent periods (CSPs) were measured over eight 
trials at three stimulus intensities (i.e., 120%, 140%, and 150% 
of the RMT), in moderately active FDI muscles (at approxi-
mately 30% of the maximum voluntary contraction).
20 TMS 
stimuli were delivered randomly 5 s apart, and eight stimuli 
were delivered at each stimulus intensity. The CSP was de-
fined as the time between the first turning point of a stimulus-
induced MEP and the first reoccurrence of rectified voluntary 
EMG activity. The time of the first turning point was deter-
mined by the EMG recording device. The offset times of CSPs 
were determined by a single blinded investigator (Joo EY). The 
average CSP was calculated at each stimulus intensity.
21
4) Intracortical inhibition (ICI) and intracortical facilitation (ICF) 
were determined at interstimulus intervals of 2 or 3 ms (i.e., short 
intracortical inhibition) and 10 or 15 ms (ICF) using a previ-
ously described protocol.
22,23 The conditioning stimulus was set 
to 80% of the RMT, and as such produced no changes in spinal 
cord excitability.
22 The intensities of subsequent suprathreshold 
test stimuli were adjusted to produce MEPs with a peak-to-
peak amplitude of approximately 1.5 mV at rest in all baseline 
and effect measurements. TMS intensity was adjusted before 
and after ZNS [i.e., whether the test stimulation intensity for 
ICI (1.5 mV) was re-evaluated after ZNS or was the same in-
tensity as for pre-ZNS]. Eight trials of single control test stimuli 
and eight paired stimuli of each ISI were recorded; stimuli were 
delivered 5 s apart in random order, as generated by the com-
puter program. An average of eight trials was used to define 
the peak-to-peak amplitudes of MEPs. A conditioned response 
is defined as the mean amplitude of the conditioned responses 
Table 1. Clinical characteristics of the patients
Patient 
no.
Gender
Age 
(years)
Epilepsy duration 
(months)
Seizure frequency 
(n/month)
Total number 
of seizures*
MRI Epileptic focus
ECD-SPECT
(reduced rCBF)
1 M 36 12 0.5 6 HIS in hippo L temporal B temporal
2 M 29 6 0.5 3 HIS in hippo R temporal R temporal
3 F 35 4 2.5 10 HIS in hippo R temporal Normal
4 F 39 10 0.25 2.5 HIS in hippo R temporal Normal
5 M 21 5 2 10 Normal L temporal Normal
6 M 33 9 0.5 4.5 Normal L temporal Normal
7 F 37 4 1.5 6 Normal L temporal Normal
8 M 23 3 1 3 Normal L temporal Normal
9 F 25 9 1 9 Normal L temporal L temporal
10 M 24 12 0.5 6 Normal L temporal Normal
11 M 41 14 1 14 Normal R temporal R temporal
12 M 37 3 2 6 Normal R temporal Normal
13 F 26 9 1 9 Normal L temporal L frontotemporal
14 F 30 2.5 5 12.5 Normal R temporal Normal
15 M 35 7 1 7 Normal R temporal Normal
16 F 21 11 0.5 5.5 Normal R temporal B temporal
17 M 29 10 2 20 Normal L temporal L temporal
18 F 22 9 1.5 13.5 Normal L temporal B temporal
19 M 28 2 1.5 3 Normal L occipital Normal
20 F 25 6 1 6 Normal L frontal L frontotemporal
21 M 23 7 2 14 Normal R frontal Normal
22 M 37 8 1 8 Normal L parietal Normal
23 M 25 12 2.5 30 Normal R parietal R temporoparietal
24 M 24 7 1 7 Normal R frontocentral R frontal
*Number of seizures before the first transcranial magnetic stimulation (i.e., before zonisamide treatment). 
MRI: magnetic resonance imaging, ECD-SPECT: 99mTc-ethylcysteinate dimer single-photon-emission computed tomography, rCBF: re-
gional cerebral blood flow, HIS: high signal intensity in the unilateral hippocampus on brain MRI, HA: hippocampal atrophy in the unilater-
al hippocampus on brain MRI, R: right, L: left.Effect of Zonisamide on Cortical Excitability
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belonging to the ISI, and is expressed as a percentage of the 
mean amplitude of the unconditioned test responses.
All five motor cortex excitability parameters were measured 
before (before ZNS) and 3.5 hours after (after ZNS) ZNS ad-
ministration, adjusted to the pharmacokinetics of the ZNS. The 
plasma ZNS concentration peaked at 2-5 hours after adminis-
tering single oral doses of 200-mg ZNS in healthy volunteers.
24,25 
However, actual serum concentrations of ZNS during TMS ses-
sions were not measured in the present study because no assay 
method for measuring ZNS is currently available in Korea.
TMS parameters were obtained in both epileptic and nonep-
ileptic hemispheres. TMS parameters in these hemispheres were 
compared to document interhemisphere differences before ZNS 
and after ZNS. None of the 24 patients had a seizure during the 
5 days before the TMS studies were performed.
The investigators who took measurements and analyzed the 
raw data were blinded to the experiment details until all data 
had been acquired. Stimulation sessions lasted approximately 
1.5-2 hours. Consent was obtained from all patients after the 
study protocol had been explained to them. The Institutional 
Review Board at Samsung Medical Center authorized the in-
formed consent form and the study protocol.
Statistical	analysis
To investigate the effect of ZNS on cortical excitability, the pair-
ed t-test was used to compare paired TMS parameters (RMT, 
MEP, CSP, and ICI/ICF) before and after ZNS administration. 
The parametric paired t-test or the nonparametric Wilcoxon’s 
signed rank test was used for normally and not-normally dis-
tributed TMS parameters measured before and after ZNS ad-
ministration. Multiple comparisons were performed using Bon-
ferroni’s correction. The Mann-Whitney test was used to per-
form interhemisphere comparisons of TMS parameters (epilep-
tic and nonepileptic hemispheres). Repeated-measures ANOVA 
was used to compare the changes in MEP or CSP values induced 
by ZNS at different stimulus intensities and in ICI or ICF val-
ues by the interstimulus interval. The level of statistical signif-
icance in all analyses was set at p<0.05. Data are expressed as 
mean±SEM values.
Results
Patients’ characteristics
The patients were 29.3±6.3 years old (range 21-41 years) and 
had suffered from epilepsy for 7.6±3.3 months (2-14 months). 
All patients underwent brain MRI and 
99mTc-ethylcysteinate 
dimer single-photon-emission computed tomography within 
1 year of diagnosis. Four of the 24 patients exhibited brain 
MRI abnormalities. The scalp EEG recording confirmed the 
location of the epileptic focus in all cases.
Four of the patients showed atrophy and signal changes in 
the unilateral hippocampus on MRI, and definite interictal ep-
ileptiform discharges were recorded in the ipsilateral temporal 
region to hippocampal atrophy during routine EEG recordings. 
Of these patients, three (1, 2, and 3 patients) had a history of com-
plex focal seizures (dialeptic or automotor seizures after abdomi-
nal aura), and the remaining patient (4 patient) had complex par-
tial seizures followed by occasional secondarily generalized 
SGTCS.
Eight patients with a history of secondarily generalized 
SGTCS exhibited EEG seizures as well as interictal spikes re-
corded in the left temporal (5-10 patients) or right temporal 
lobes (11 and 12 patients) during routine EEG recordings.
Eleven patients with normal MRI findings underwent long-
term video-EEG monitoring to confirm the epileptic focus. 
Four of these patients (13-16 patients) exhibited typical com-
plex focal seizures (dialeptic or automotor seizures with a 
preceding abdominal aura) followed by secondarily generalized 
tonic-clonic seizures arising from the ipsilateral mesial tempo-
ral area during their monitoring periods. Two patients (17 and 
18 patients) exhibited auditory aura followed by complex focal 
seizures arising from the left lateral temporal region. 19 Patient 
exhibited visual aura and brief complex focal seizures followed 
by secondarily generalized SGTCS with ictal repetitive spikes 
arising from left occipital lobe. In two patients with a history 
of nocturnal generalized SGTCS, video-EEG monitoring re-
vealed frequent interictal sharp waves and ictal EEG dis-
charges on the left (20 patient) or right (21 patient) frontal 
lobe during sleep. 22 and 23 patients, who suffered from so-
matosensory auras (paresthesia or tingling sensation in unilat-
eral face or arm), followed by complex focal seizures (version 
of head to the contralateral side) and secondarily generalized 
SGTCS exhibited frequent spikes or polyspikes and ictal 
EEG discharges on the contralateral parietal region to the side 
of somatosensory auras.
A 24-year-old male (24 patient) with a history of episodes of 
left-arm clonic seizures without loss of consciousness and noctur-
nal generalized SGTCS had interictal spikes in the right fronto-
central area on sleep EEG recordings. The clinical information 
and 
99mTc-ethylcysteinate dimer single-photon-emission comput-
ed tomography findings are summarized in Table 1.
ZNS dosage regimen and duration of administration
Fourteen of our 24 patients (58%) achieved a seizure-free state 
at a ZNS dosage of 200 mg/day between treatment weeks 6 
and 8. Eight patients suffered habitual complex partial seizures 
or simple partial seizures at ZNS 200 mg/day; three of these be-
came seizure free at 250 mg/day, and the other five became sei-
zure free at 300 mg/day. Two patients were seizure free at 200   
mg/day, but required dosage reduction to 150 or 175 mg/day due Joo EY et al.
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to a loss of appetite, weight loss, and dizziness. Nevertheless, 
these patients maintained a seizure-free state. No patient expe-
rienced an unexpected serious adverse event.
Effects of ZNS on cortical excitability
Parametric statistical analyses were used in the study because 
we were able to assume that the data were normally distribut-
ed after the normality testing (Table 2).
The RMT did not change after ZNS administration in ei-
ther hemisphere (p>0.05, paired t-test with multiple compari-
sons). Peak-to-peak MEP amplitudes increased with the stim-
ulus intensity. ZNS significantly reduced the MEP amplitudes 
in epileptic hemispheres at all stimulus intensities (p=0.005–
0.006). ZNS did not suppress the MEP amplitudes in nonepi-
leptic hemispheres (Fig. 1). The CSP lengthened approxi-
mately linearly with intensity, but ZNS did not change the CSP 
of epileptic and nonepileptic hemispheres. Short intracortical 
inhibition and ICF were unchanged by ZNS in both hemisp-
heres. Repeated-measures ANOVA did not reveal a significant 
main effect for either intensity or ISI (p>0.05).
Discussion
We found that therapeutic doses of ZNS significantly decreased 
the MEP amplitudes only in the epileptic hemisphere of focal 
epilepsy patients. Mean MEP amplitudes in focal epilepsy pa-
tients before ZNS showed a tendency to be higher in the epi-
leptic hemisphere than in the nonepileptic hemisphere at all sti-
mulus intensities, although the difference did not reach statistical 
significance. Some authors noted that the effect of AEDs on MEP 
size appeared to be not so clearly related to different modes 
of action.
7 Others have argued that only MEP amplitude is af-
fected and that it must therefore be the most sensitive measure 
of AED action.
18,26
In the present study, ZNS significantly decreased MEP am-
plitudes only in epileptic hemispheres, and not in nonepileptic 
hemispheres. There is some evidence from animal experiments 
that MEPs are suppressed in the hemipshere ipsilateral to the ep-
ileptic focus. In a limbic seizure model induced by a unilater-
Table 2. ZNS-induced changes in cortical excitability in focal epilepsy patients
Epileptic hemispheres Nonepileptic hemispheres
Pre-ZNS Post-ZNS p Pre-ZNS  Post-ZNS p*
Resting motor threshold (%) 040.8±1.9 043.5±2.1 0.006* 040.7±1.6 041.0±1.4 0.665
Motor evoked potential amplitude (mV)
    Stimulus intensity 120% 0.965±0.102 0.495±0.080 0.005* 0.735±0.109 0.751±0.144 0.779
                                  140% 1.699±0.197 0.981±0.116 0.005* 1.565±0.231 1.492±0.262 0.386
                                  150% 2.229±0.276 1.485±0.232 0.006* 1.832±0.266 1.814±0.268 0.815
Cortical silent periods (ms)
    Stimulus intensity 120% 110.3±5.7 114.2±5.8 0.530  115.3±7.5 111.5±7.5 0.600 
                                  140% 143.1±6.9 151.6±6.3 0.145  156.3±6.3 164.9±7.2 0.192
                                  150% 176.6±12.2 183.0±6.7 0.585  186.9±15.1 178.0±7.1 0.572
Intracortical inhibition (%)
    Interstimulus interval 2 ms 025.5±2.7 028.0±3.7 0.572  030.5±4.8 024.1±3.1 0.259 
                                            3 ms 027.8±3.3 026.4±2.5 0.714  032.6±4.5 029.4±5.4 0.700
Intracortical facilitation (%)
    Interstimulus interval 10 ms 116.7±18.1 101.9±8.1 0.425  118.9±13.2 131.7±18.9 0.593
                                             15 ms  123.9±19.2 135.2±14.9 0.537  120.8±10.2 137.5±15.5 0.315
Data are mean±SEM values. pre-ZNS: before ZNS administration, post-ZNS: after zonisamide administration. 
*p<0.05, paired t-test after Bonferroni’s correction for multiple comparisons.
ZNS: zonisamide.
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Fig. 1. Changes in motor evoked potential (MEP) amplitudes af-
ter zonisamide (ZNS) administration in epilepsy patients. After ZNS 
treatment, MEP amplitudes were significantly reduced at 120%, 
140%, and 150% of the resting motor threshold (RMT) stimulation 
only in epileptic hemispheres. *Paired t-test after applying Bonferro-
ni’s correction for multiple comparisons (p<0.05). Data are present-
ed as medians (horizontal lines through the boxes) with the first and 
third quartiles (lower and upper lines, respectively) and the smallest 
and largest values (whiskers extending from the ends of the boxes). 
Pre-ZNS: before ZNS administration, Post-ZNS: after the ZNS ad-
ministration, RMT: resting motor threshold.
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al microinjection of kainic acid into the rat amygdala, ZNS at 
100 mg/kg significantly decreased the local cerebral glucose uti-
lization in the ipsilateral sensorimotor cortex and hippocampus, 
in contrast to normal saline injection.
27 During limbic status ep-
ilepticus, ZNS markedly attenuated seizures in the sensorimo-
tor cortex, and a high uptake of 
14C-ZNS was noted ipsilater-
ally in the sensorimotor cortex, parietal cortex, and thalamus in 
an autoradiographic study.
28 These experiments demonstrate that 
ZNS inhibits seizure propagation from the epileptic hemisphere 
in focal epilepsy and suggest that the cortical excitability of ep-
ileptic hemispheres is more susceptible to attenuation by ZNS. 
However, those authors recognized that despite various studies 
of the effects of ZNS, the mechanism of its anticonvulsive ac-
tion remains unclear.
We have previously reported the effects of ZNS on cortical 
excitability in patients with IGE.
18 With a similar dosage admin-
istered for a similar period, we found that ZNS decreased MEP 
amplitudes bilaterally in IGE. One of the mechanisms of ac-
tion of ZNS that supports its efficacy in generalized seizures 
is blockage of the low-threshold T-type calcium channels, which 
may confer efficacy against absence seizures.
29-32 It is not un-
common to find disappearance of generalized epileptiform dis-
charges after treatment with ZNS in patients with IGE.
33,34 
These findings support the bilateral reduction of MEPs in pa-
tients with IGE and unilateral decline in epileptic hemispheres 
in focal epilepsy patients after ZNS administration.
RMT findings in different studies have yielded disparate 
findings: some have found that RMTs were reduced in untreat-
ed IGE patients,
35 some have found normal RMTs,
36,37 and oth-
ers have found increased RMTs.
38 In the present study, the mean 
RMT appeared to be higher in the epileptic hemisphere than in 
the nonepileptic hemisphere at all stimulus intensities, but this 
finding did not reach statistical significance. Moreover, the mean 
RMT was not changed after treatment of ZNS in either the ep-
ileptic or nonepileptic hemisphere. Another study of 27 drug-na-
ïve focal epilepsy patients revealed a significant interhemisp-
here RMT difference (i.e., higher values in the epileptic hemis-
phere).
11 Their frontal lobe epilepsy patients also did not have 
definite MRI abnormalities (while it was not clear whether their 
epileptic foci in the frontal lobe were located in the motor cor-
tex or not). Three of our 24 patients also had no MRI lesion, al-
though an epileptic focus in the left or right frontal lobe was 
determined by long-term video-EEG monitoring. However, it 
is unlikely that epileptic focus per se affected the RMT in this 
study, because foci were located far beyond the motor cortex 
(i.e., two in the prefrontal area and one in the orbitofrontal cor-
tex). It could be speculated that not only motor cortex involve-
ment of epileptic focus but also seizure propagation to the mo-
tor cortex may induce RMT changes. Overall, the differential 
results from various TMS studies may be attributable to the lo-
cation of the epileptic focus, seizure type, the time from last sei-
zure, and the frequency and propagation pattern of the seizures.
TMS has been used to characterize the changes in motor cor-
tex excitability associated with AED administration (mostly 
single dose) in healthy volunteers.
39,40 A single oral dose of car-
bamazepine in healthy volunteers was found to increase the 
RMT without changing either ICI or ICF,
41 whereas 1 week of 
carbamazepine in patients with neuropathic pain did not change 
the RMT.
42 Furthermore, single oral doses of lamotrigine in heal-
thy volunteers increased the RMT without changing either ICI 
or ICF,
40 but chronic lamotrigine treatment in a group of healthy 
volunteers undergoing a 5-week session elevated the RMT and 
ICI, and these changes occurred in parallel with an increase in 
plasma levels.
43 The ability to transfer short-term effects to the 
longer term is limited given known changes in the rate of me-
tabolism, drug-induced changes in receptor densities or recep-
tor coupling efficiencies, and sensitization.
43 Thus, the short- and 
long-term effects of an AED may differ. Furthermore, the find-
ings of TMS studies may differ between healthy volunteers and 
epilepsy patients. In the present study, we investigated the ef-
fects of the long-term administration of ZNS on the brains of 
drug-naïve epilepsy patients, and it is evident based on the find-
ings of previous studies that the short- and long-term effects of 
ZNS might be quite different.
The findings of the present TMS study suggest that ZNS 
alters cortical excitability in brains with focal epilepsy. The 
MEP amplitudes were significantly reduced after ZNS ad-
ministration only in epileptic hemispheres, and they may be 
useful for evaluating ZNS-induced changes in cortical excit-
ability. Other TMS parameters were unaffected by ZNS.
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